Cargando…
Hepatitis C in European prisons: a call for an evidence-informed response
Globally, over 10 million people are held in prisons and other places of detention at any given time. People who inject drugs (PWID) comprise 10-48% of male and 30-60% of female prisoners. The spread of hepatitis C in prisons is clearly driven by injection drug use, with many infected prisoners unaw...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178549/ https://www.ncbi.nlm.nih.gov/pubmed/25252822 http://dx.doi.org/10.1186/1471-2334-14-S6-S17 |
_version_ | 1782336975657762816 |
---|---|
author | Arain, Amber Robaeys, Geert Stöver, Heino |
author_facet | Arain, Amber Robaeys, Geert Stöver, Heino |
author_sort | Arain, Amber |
collection | PubMed |
description | Globally, over 10 million people are held in prisons and other places of detention at any given time. People who inject drugs (PWID) comprise 10-48% of male and 30-60% of female prisoners. The spread of hepatitis C in prisons is clearly driven by injection drug use, with many infected prisoners unaware of their infection status. Risk behaviour for acquisition of hepatitis C via common use of injecting equipment is widespread in many prison settings. In custodial settings, effective and efficient prevention models applied in the community are very rarely implemented. Only approximately 60 out of more than 10,000 prisons worldwide provide needle exchange. Thus, HCV prevention is almost exclusively limited to verbal advice, leaflets and other measures directed to cognitive behavioural change. Although the outcome of HCV antiviral treatment is comparable to non-substance users and substance users out of prison, the uptake for antiviral treatment is extremely low. Based on a literature review to assess the spread of hepatitis C among prisoners and to learn more about the impact for the prison system, recommendations regarding hepatitis C prevention, screening and treatment in prisons have been formulated in this article. |
format | Online Article Text |
id | pubmed-4178549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41785492014-10-14 Hepatitis C in European prisons: a call for an evidence-informed response Arain, Amber Robaeys, Geert Stöver, Heino BMC Infect Dis Review Globally, over 10 million people are held in prisons and other places of detention at any given time. People who inject drugs (PWID) comprise 10-48% of male and 30-60% of female prisoners. The spread of hepatitis C in prisons is clearly driven by injection drug use, with many infected prisoners unaware of their infection status. Risk behaviour for acquisition of hepatitis C via common use of injecting equipment is widespread in many prison settings. In custodial settings, effective and efficient prevention models applied in the community are very rarely implemented. Only approximately 60 out of more than 10,000 prisons worldwide provide needle exchange. Thus, HCV prevention is almost exclusively limited to verbal advice, leaflets and other measures directed to cognitive behavioural change. Although the outcome of HCV antiviral treatment is comparable to non-substance users and substance users out of prison, the uptake for antiviral treatment is extremely low. Based on a literature review to assess the spread of hepatitis C among prisoners and to learn more about the impact for the prison system, recommendations regarding hepatitis C prevention, screening and treatment in prisons have been formulated in this article. BioMed Central 2014-09-19 /pmc/articles/PMC4178549/ /pubmed/25252822 http://dx.doi.org/10.1186/1471-2334-14-S6-S17 Text en Copyright © 2014 Arain et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Arain, Amber Robaeys, Geert Stöver, Heino Hepatitis C in European prisons: a call for an evidence-informed response |
title | Hepatitis C in European prisons: a call for an evidence-informed response |
title_full | Hepatitis C in European prisons: a call for an evidence-informed response |
title_fullStr | Hepatitis C in European prisons: a call for an evidence-informed response |
title_full_unstemmed | Hepatitis C in European prisons: a call for an evidence-informed response |
title_short | Hepatitis C in European prisons: a call for an evidence-informed response |
title_sort | hepatitis c in european prisons: a call for an evidence-informed response |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178549/ https://www.ncbi.nlm.nih.gov/pubmed/25252822 http://dx.doi.org/10.1186/1471-2334-14-S6-S17 |
work_keys_str_mv | AT arainamber hepatitiscineuropeanprisonsacallforanevidenceinformedresponse AT robaeysgeert hepatitiscineuropeanprisonsacallforanevidenceinformedresponse AT stoverheino hepatitiscineuropeanprisonsacallforanevidenceinformedresponse |